ASH Annual Meeting and Exposition | Conference

Brexu-Cel Displays Comparable Efficacy Across Age Groups in Relapsed/Refractory B-ALL

December 8th 2024

Brexucabtagene autoleucel demonstrated similar efficacy across age groups of patients with relapsed/refractory B-cell acute lymphoblastic leukemia

Asciminib Continues to Best SOC TKIs as Secondary End Points of ASC4FIRST Trial are Met

December 8th 2024

Treatment with asciminib results in superior efficacy and safety vs investigator-selected TKIs in CML according to updated 96-week data from ASC4FIRST.

Epcoritamab Monotherapy Induces Complete Responses in R/R CLL

December 8th 2024

Single-agent, subcutaneous epcoritamab generated deep responses in patients with relapsed/refractory chronic lymphocytic leukemia.

Olverembatinib May Be Effective in Second Line for CP-CML

December 8th 2024

Olverembatinib showed potential in patients with chronic-phase chronic myeloid leukemia with prior exposure to first-line second-generation TKIs.

US Real-World Analysis Supports Clinical Benefit of Tafasitamab in R/R DLBCL

December 8th 2024

Data from a retrospective analysis showcase the real-world effectiveness of tafasitamab for relapsed/refractory DLBCL in the United States.

FS118 Showcases Modest Efficacy in Relapsed/Refractory DLBCL

December 8th 2024

FS118, an investigational LAG-3/PD-L1 bispecific antibody, demonstrated an encouraging objective response rate in the relapsed/refractory DLBCL setting.

Dr Kaddoura on Genomic Determinants of Outcomes in IGH/CCND1+ Myeloma Treated With Venetoclax

December 8th 2024

Marcella Ali Kaddoura, MD, discusses genomic determinants of clinical outcomes in myeloma with t(11;14)(CCND1;IGH) treated with venetoclax.

Dr Zackon on the Use of Bispecific Antibodies in the Community Setting for R/R Myeloma

December 8th 2024

Ira Zackon, MD, discusses findings on the real-world utilization of bispecific antibodies in the treatment of relapsed/refractory multiple myeloma in the community oncology setting.

Dr Jurczak on the Efficacy and Safety of Nemtabrutinib in R/R Follicular Lymphoma

December 8th 2024

Wojciech Jurczak, MD, PhD, discusses the safety and efficacy of nemtabrutinib, a noncovalent reversible BTK inhibitor in relapsed or refractory follicular lymphoma.

Oral Revumenib-Based Combo Produces Responses in R/R AML

December 8th 2024

Revumenib plus decitabine/cedazuridine and venetoclax produced responses in relapsed/refractory acute myeloid leukemia.

D-VRd Deepens MRD Responses in Transplant-Ineligible or -Deferred Newly Diagnosed Myeloma

December 8th 2024

Daratumumab plus VRd improved MRD responses and progression-free survival in transplant-ineligible or -deferred newly diagnosed multiple myeloma.

Revumenib Displays Activity in Relapsed/Refractory KMT2A+ Acute Leukemias

December 8th 2024

Revumenib demonstrated meaningful responses in patients with relapsed or refractory KMT2Ar acute leukemia.

Smoking May Increase Genetic Mutations, Disease Progression in MDS

December 7th 2024

Findings showed the potential impact of smoking on disease progression and survival in patients with myelodysplastic syndrome.

Blinatumomab Plus Chemo Increases DFS Rates in Standard-Risk Pediatric B-ALL

December 7th 2024

Blinatumomab plus chemotherapy significantly improved 3-year DFS rates vs chemotherapy alone in pediatric patients with standard-risk pediatric B-ALL.

Bicistronic CD19/CD22-Directed CAR T-Cell Therapy Is Safe, Elicits Durable Responses in Pediatric R/R B-ALL

December 7th 2024

Treatment with bicistronic CD19/CD22 CAR T-cell therapy led to high 1-year EFS and OS rates among children with relapsed/refractory B-ALL.

Drs Baljevic and Cortes Preview Upcoming Studies and Emerging Data From ASH 2024

December 6th 2024

Muhamed Baljevic, MD, FACP and Jorge Cortes, MD, discuss upcoming studies and emerging data being presented at the 2024 ASH Annual Meeting.

Dr Jain on the Importance of Novel Therapies in Pediatric Patients With Bleeding Disorders

December 15th 2023

Akshat Jain, MBBS, discusses the importance of novel therapies in the treatment of pediatric patients with beleeding disorders.

Dr Chari on Findings From the MonumenTAL-1 Trial in Relapsed/Refractory Multiple Myeloma

December 15th 2023

Ajai Chari, MD, discusses the efficacy of treating patients with less frequent or lower intensity dosing of talquetamab in patients with relapsed/refractory multiple myeloma, as evaluated in the phase 1/2 MonumenTAL-1 study.

Zanubrutinib Favored Over Bendamustine/Rituximab Combination Across Biomarker Subgroups in CLL/SLL Without del(17p)

December 15th 2023

Treatment with zanubrutinib conferred a PFS benefit vs bendamustine plus rituximab across most biomarker subgroups of patients with treatment-naive chronic lymphocytic leukemia or small lymphocytic lymphoma without del(17p), according to findings from the phase 3 SEQUOIA trial.

Acquired BTK and PLCG2 Mutations May Not Drive Progression After Zanubrutinib/Ibrutinib Treatment in Relapsed CLL

December 14th 2023

The majority of patients with relapsed CLL treated with zanubrutinib or ibrutinib in the phase 3 ALPINE study did not acquire a BTK or PLCG2 mutation at the time of disease progression, indicating that these mutations may not be the primary drivers of resistance and relapse in this population.